Address
Amgen Inc
One Amgen Center Drive
Thousand Oaks, CA 91320
United States
Phone
Website
VCID: 116834
Profile
Corporate information
Official name
Amgen Incorporated
Registration country
Official identities
US CIK 0000318154
Affiliated entities
Investment activity status
Active investor
Team
Current employees
![[node:title] photo](/sites/default/files/styles/icon/public/default_images/icon-person.png?itok=8SSzz6Wf "[node:title] photo"){kind=icon}
|
Robert Bradway | ||
|
|
Kevin Sharer |
Funding
Funding rounds
(1 May 2006)
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Skyline Ventures | Life Sciences venture capital firm | United States |
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Asset Management Co Venture Capital | Early-stage venture capital firm investing in digital health. | United States | |
|
Royalty Pharma AG | Acquisition of royalty interests in leading pharmaceutical and biotechnology products and holding them as part of a diversified portfolio | United States |
Cap Table
Current and past shareholders
| Investor | Contacts | Round | |
|---|---|---|---|
|
|
Asset Management Co Venture Capital Early-stage venture capital firm investing in digital health. |
+1 (650) 494-7400 |
N/A |
|
|
Royalty Pharma AG Acquisition of royalty interests in leading pharmaceutical and biotechnology products and holding them as part of a diversified portfolio |
N/A | |
|
|
Skyline Ventures Life Sciences venture capital firm |
+1 (203) 564-1596 |
Series C |
Investments
Investment preferences
Selected investments
| Company | Country | Date | Notes | ||
|---|---|---|---|---|---|
|
VenBio Global Strategic Fund II LP |
Cayman Islands | 6 May 2016 | Fund Closing Initial investment. Round participant. Active |
|
|
Onyx Pharmaceuticals Inc |
United States | 25 Aug 2013 | Acquisition USD 10,500,000,000 (USD 10,500,000,000) deal size. Initial investment. Round participant. Active |
|
|
|
Miragen Therapeutics Inc Ddeveloper of cardiovascular and muscle disease therapeutics based on microRNA biology. |
United States | 1 Apr 2012 | Series B Initial investment. Round participant. Active |
|
|
|
Theraclone Sciences Inc |
United States | 1 Sep 2011 | Series B |
|
|
|
Biovex Inc Biotechnology company developing new generation biologics for the treatment of cancer and infectious disease. |
United States | 4 Mar 2011 | Acquisition Active |
|
|
|
Epizyme Inc Focusing on the discovery and development of innovative drugs targeting epigenetic enzymes, in particular histone methyltransferases (HMTs). |
United States | 1 Oct 2009 | Series B Active |
|
|
|
Avidia Inc |
United States | 1 May 2005 | Series B Active |
|
|
|
Alantos Pharmaceuticals Holding Inc Discoverer and developer of small molecule drugs for osteoarthritis/ inflammation and type II diabetes. |
United States | N/A |
||
|
|
Calistoga Pharmaceuticals Inc Biopharmaceutical company dedicated to developing targeted therapies to improve the health of patients with cancer or inflammatory diseases. |
United States | N/A |
||
|
|
TetraLogic Pharmaceuticals A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. |
United States | N/A Active |